Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis

Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis

(2020) Lars Bossen et al.   LIVER INTERNATIONAL

Macrophage markers and innate immunity in cirrhosis

(2020) Henning Grønbæk et al.   JOURNAL OF HEPATOLOGY

Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment

(2018) Tea Lund Laursen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

(2018) Maria Eugenia Guicciardi et al.   JOURNAL OF HEPATOLOGY

Rapid and persistent decline in soluble CD163 with successful direct-acting antiviral therapy and associations with chronic hepatitis C histology

(2018) Tea Lund Laursen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis

(2018) Amandeep K Dhillon et al.   LIVER INTERNATIONAL

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis

(2017) Elisabeth M de Vries et al.   GUT

EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis

(2017) Gideon M. Hirschfield et al.   JOURNAL OF HEPATOLOGY

Primary sclerosing cholangitis – a comprehensive review

(2017) Tom H. Karlsen et al.   JOURNAL OF HEPATOLOGY

The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients

(2017) Thomas Damgaard Sandahl et al.   PLoS One

Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis

(2016) H. Grønbaek et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis

(2016) T. D. Sandahl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)

(2016) Henning Grønbæk et al.   JOURNAL OF HEPATOLOGY

The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation

(2016) Tea L. Laursen et al.   LIVER INTERNATIONAL

Prognostic biomarkers and surrogate end points in PSC

(2016) Mette Vesterhus et al.   LIVER INTERNATIONAL

Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis

(2015) Mette Vesterhus et al.   HEPATOLOGY

Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process

(2015) Cyriel Y. Ponsioen et al.   HEPATOLOGY

Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery

(2015) Konstantin Kazankov et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Hepatic Macrophage Activation and the LPS Pathway in Patients With Alcoholic Hepatitis: A Prospective Cohort Study

(2014) Thomas Damgaard Sandahl et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis

(2014) B. Eksteen   BRITISH MEDICAL BULLETIN

Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C

(2014) Konstantin Kazankov et al.   HEPATOLOGY

A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness

(2013) Sidsel Rødgaard-Hansen et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Hepatic macrophage activation predicts clinical decompensation in chronic liver disease

(2013) Anthony Rode et al.   GUT

The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values

(2013) Ralf Lichtinghagen et al.   JOURNAL OF HEPATOLOGY

Primary sclerosing cholangitis

(2013) Gideon M Hirschfield et al.   LANCET

Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis

(2012) H. Grønbaek et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The mannose receptor

(2012) Luisa Martinez-Pomares   JOURNAL OF LEUKOCYTE BIOLOGY

Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS

(2011) P. Holland-Fischer et al.   GUT

Soluble CD163

(2011) Holger J. Møller   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

(2010) Kirsten Muri Boberg et al.   JOURNAL OF HEPATOLOGY

Diagnosis and management of primary sclerosing cholangitis

(2009) Roger Chapman et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of cholestatic liver diseases

(2009)   JOURNAL OF HEPATOLOGY